SUTRO BIOPHARMA, INC. Operating Lease, Liability, Current
SUTRO BIOPHARMA, INC. (STRO) had Operating Lease, Liability, Current of $6.66 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Leases
us-gaap:OperatingLeaseLiabilityCurrent · last filed 2026-08-12
- 2026-06-30: Operating Lease, Liability, Current $6.66M.
- 2026-03-31: Operating Lease, Liability, Current $7.60M.
- 2025-12-31: Operating Lease, Liability, Current $7.78M.
- 2025-09-30: Operating Lease, Liability, Current $7.96M.
| Period end | Operating Lease, Liability, Current |
|---|---|
| 2026-06-30 | $6.66M 10-Q · filed 2026-08-12 |
| 2026-03-31 | $7.60M 10-Q · filed 2026-05-14 |
| 2025-12-31 | $7.78M 10-Q · filed 2026-08-12 |
| 2025-09-30 | $7.96M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $8.06M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $7.76M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $7.48M 10-K · filed 2026-03-23 |
| 2024-09-30 | $7.20M 10-Q · filed 2024-11-13 |
| 2024-06-30 | $6.93M 10-Q · filed 2024-08-13 |
| 2024-03-31 | $6.67M 10-Q · filed 2024-05-13 |
| 2023-12-31 | $6.42M 10-K · filed 2025-03-13 |
| 2023-09-30 | $6.17M 10-Q · filed 2023-11-13 |
| 2023-06-30 | $5.93M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $5.25M 10-Q · filed 2023-05-15 |
| 2022-12-31 | $4.58M 10-K · filed 2024-03-25 |
| 2022-09-30 | $2.63M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $1.12M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $1.08M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $1.04M 10-K · filed 2023-03-30 |
| 2021-09-30 | $1.45M 10-Q · filed 2021-11-10 |
| 2021-01-01 | $2.90M 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 |